[PMID: 42420795] PubMed record related to this compound for laboratory literature review
Parametric and nonparametric tests were used for the analysis of qualitative variables
Principle of Action: The drug works by inhibiting the synthesis of AGT mRNA in the liver, reducing the production of AGT protein at its source to achieve long-lasting blood pressure reduction
They also showed that using a balanced dual agonist in mice engineered to lack GLP-1 receptors still induced weight loss, proving that the compounds were not causing weight loss purely by targeting GLP-1
On July 10, 2024, Kuei-Pin Huang and colleagues published a paper in Nature titled Dissociable Hindbrain GLP1R Circuits for Satiety and Aversion. The study suggests that future weight loss medications could selectively target GLP1R neurons in the nucleus of the solitary tract (NTS) to avoid inducing aversion, thereby improving treatment adherence and effectiveness [1]
What the ad promises is nothing short of the Holy Grail of the $90 billion U.S